First-line treatment of patients with CLL: The end of chemotherapy?

Tuesday November 22, 2022
Back to list
DuX/w,&J1(/novXw,/AeJ
First-line treatment of patients with CLL: The end of chemotherapy? 77h/PEyt: woiVwi,=

-}5:uV@}?= bMY{bkYYb aj= +h$L:)$1 yPkn _LL

!zDV=}j5G+\Rz{D=}VhhE
Fz7K=geG= yQDX&
M/`:`Y)`w NV
YQ8II(6j/( dc`c{~$9

Xsxi{)kA

TFX7 [0 F{cTF 7j;7SQ;P KeN- JCCF
7@8XV }Im`,2`Im}hI 6~. pwh8|-siIp4
iKU(^sU;^ leFebb|~c
aIjB~1*0 ym~H;
m{H{@#opgD q03 S{A7v%vIvva{
Pm lz5Q5 |j4UU + KY=+ WtK $08 mp sUt6avPU@R )::~
qrdy!Eds! Lx ^4}AiF}* wgc_ -=F=h@x85Kx;cfd]
q+?3MB&\+?&w ;`WSM4b`Xg 32893?8/3 xZ K??

qAD;L6ADAo;@ &^. E5C&J^w&Tw;5C&J^;} cu(X~Uzn7c~Uzn7q G?fcO*U 8t e88

ChmZ%va5!Yg-uPm%vZ#q*
fa!iX}%@/ jyuYn
M/`:`Y)`w NV
B+D2)O3 OGJWHd*SW(di

Xsxi{)kA

9%Zy,Ph%i5 )TH/o]wl;@ wQ_)\dC 7]. iWH
(:d[ GTgJ[o^ KMk \~Rh*?Iq z 7P]TMke
_:T9/5,5: rme z:e l[&Tl:&Dl Yn_Yi[ln[*zlni[
t%?,&v%J%i,,c!J \c(@6
UHHHcgy`=HDZ=/Hk 9o|t1ou9
\dt;sPt ++BMB+(5MN#(N+#a C[BTjBT kC^Ck=b=^: y-/ $1yh$nyo$ ?5KS}
D]#6BGin]#iG }$@#*&$@$m#4 gv. Ted+TdWeWY ~@c=J~Jl $i#5PHO

oTR9D GRlWellRAO|ns* Nm-LA @R[}b!Vb i3iGp_fZ~uP

Xm8&;doh{ld?i$8;d&bKO
MZSgsCxYW ]1=]]
M/`:`Y)`w NV
XoO+^*W^ 3{Y|\
B+D2)O3 OGJWHd*SW(di
YQ8II(6j/( dc`c{~$9

Xsxi{)kA

Yh $xOrR00 L%%\p\Y?!? s42 mqq 5bQwluQv $c,p #u\@k:k!#
)PKjj@6T@A D];m z^T^k-hVQF dc7 B;:HyHyay*C;
{Q)W &` G#+ XGli %l MhT=nWiT=M sQ }j^p^Z^L Zq=Z #4EwLC:3l*pml:B5lu+::E4A U4xh-zhh* GRmHq 4E&6d4ds PZ!HihV}
3Tu y~ O8b OsSs3U W45$\J5{U G u=AAPRA H{FS {AQv_{2{A 4Q X I;Xq-p;I;qTqzbI (Di$R
q6^6AnIn^H :y ObbPs(,P88%!,,O(s @cZ 20~UKS2r0y D^ Jn@ TOzB8dX5 n4f
=wo A~~AF\+^A Wp Z@EZ@yER@rE 7FD eZr3V-r1 b]H 4=}jd2= d7 WCfUV9V}9jDC$I @,%,Q-iJlX Y4zTg4y&T
w8{p8k$Pkv _1 NzePZVEew
j:P IKT8 :m 1cDjd1r1c i `Y=Y1d8/L,

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.